Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies

Cancer Treatment Reviews

Volumn 36, Issue 8, 2010, Pages 637-646

  Bacher, Ulrike ^a   Kohlmann, Alexander ^b   Haferlach, Torsten ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Acute leukaemias; Classification; Diagnosis; Diagnostic algorithms; Gene expression profiling (GEP); Hematology; Leukemia; Lymphatic malignancies

Indexed keywords

AZACITIDINE; IMATINIB; LENALIDOMIDE; THALIDOMIDE; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; CANCER DIAGNOSIS; CANCER THERAPY; GENE DELETION; GENE EXPRESSION PROFILING; HUMAN; LYMPHOBLASTOMA; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICROARRAY ANALYSIS; PROGNOSIS;

EID: 78349309925     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.05.002     Document Type: Review

References (122)

1. Marcucci G., Mrozek K., Bloomfield C.D. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005, 12:68-75.
2. Haferlach T., Bacher U., Haferlach C., Kern W., Schnittger S. Insight into the molecular pathogenesis of myeloid malignancies. Curr Opin Hematol 2007, 14:90-97.
3. Mrozek K., Harper D.P., Aplan P.D. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009, 23:991-1010.
4. Swerdlow S., Campo E., Lee Harris N., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon. 4th ed.
5. Iqbal J., Liu Z., Deffenbacher K., Chan W.C. Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol 2009, 22:191-210.
6. Tallman M.S. New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol 2006, 19:311-320.
7. Tallman M.S., Nabhan C., Feusner J.H., Rowe J.M. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002, 99:759-767.
8. Hu J., Liu Y.F., Wu C.F., et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009, 106:3342-3347.
9. Gokbuget N., Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009, 46:64-75.
10. Schultz K.R., Bowman W.P., Aledo A., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009, 27:5175-5181.
11. Ottmann O.G., Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematol Am Soc Hematol Educ Program 2009, 1:371-381.
12. Haferlach T., Bacher U., Kern W., Schnittger S., Haferlach C. Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol 2007, 86:311-327.
13. Perkins A.S., Friedberg J.W. Burkitt lymphoma in adults. Hematol Am Soc Hematol Educ Program 2008, 1:341-348.
14. Van Loo P., Tousseyn T., Vanhentenrijk V., et al. T cell/histiocyte rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica 2010, 95:440-448.
15. de Jong D., Rosenwald A., Chhanabhai M., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007, 25:805-812.
16. Dave S.S., Fu K., Wright G.W., et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006, 354:2431-2442.
17. Rosenwald A., Ott G. Burkitt lymphoma versus diffuse large B-cell lymphoma. Ann Oncol 2008, 19(Suppl. 4):iv67-iv69.
18. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
19. Yeoh E.J., Ross M.E., Shurtleff S.A., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
20. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628.
21. Haferlach T., Kohlmann A., Schnittger S., et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005, 106:1189-1198.
22. Bullinger L., Dohner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350:1605-1616.
23. Radmacher M.D., Marcucci G., Ruppert A.S., et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 2006, 108:1677-1683.
24. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758-764.
25. de Jonge H.J., de Bont E.S., Valk P.J., et al. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood 2009, 114:2869-2877.
26. Ebert B.L., Galili N., Tamayo P., et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008, 5:e35.
27. Raza A., Mehdi M., Mumtaz M., et al. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008, 113:1596-1604.
28. Mullighan C.G., Downing J.R. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia 2009, 23:1209-1218.
29. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
30. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
31. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
32. Wouters B.J., Lowenberg B., Delwel R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 2009, 113:291-298.
33. Willman C.L. Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML?. Best Pract Res Clin Haematol 2008, 21:21-28.
34. Southern E., Mir K., Shchepinov M. Molecular interactions on microarrays. Nat Genet 1999, 21:5-9.
35. Lipshutz R.J., Fodor S.P., Gingeras T.R., Lockhart D.J. High density synthetic oligonucleotide arrays. Nat Genet 1999, 21:20-24.
36. Careccia S., Mainardi S., Pelosi A., et al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene 2009, 28:4034-4040.
37. Tiu R.V., Gondek L.P., O'Keefe C.L., et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 2009, 27:5219-5226.
38. Kawamata N., Ogawa S., Gueller S., et al. Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol 2009, 37:937-946.
39. Staal F.J., Cario G., Cazzaniga G., et al. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia 2006, 20:1385-1392.
40. Kohlmann A., Schoch C., Dugas M., et al. Pattern robustness of diagnostic gene expression signatures in leukemia. Genes Chromosomes Cancer 2005, 42:299-307.
41. Shi L., Reid L.H., Jones W.D., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006, 24:1151-1161.
42. Ioannidis J.P. Is molecular profiling ready for use in clinical decision making?. Oncologist 2007, 12:301-311.
43. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868.
44. Mardia K., Kent J., Bibby J. Multivariate analysis 1979, Academic Press, London.
45. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005, 23:7332-7341.
46. Schoch C., Kohlmann A., Schnittger S., et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci USA 2002, 99:10008-10015.
47. Debernardi S., Lillington D.M., Chaplin T., et al. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 2003, 37:149-158.
48. Ross M.E., Mahfouz R., Onciu M., et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004, 104:3679-3687.
49. Verhaak R.G., Wouters B.J., Erpelinck C.A., et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 2009, 94:131-134.
50. Kohlmann A., Schoch C., Dugas M., et al. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia 2005, 19:953-964.
51. Schoch C., Kern W., Kohlmann A., et al. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005, 43:227-238.
52. Lindvall C., Furge K., Bjorkholm M., et al. Combined genetic and transcriptional profiling of acute myeloid leukemia with normal and complex karyotypes. Haematologica 2004, 89:1072-1081.
53. Rucker F.G., Bullinger L., Schwaenen C., et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006, 24:3887-3894.
54. Schoch C., Haferlach T., Bursch S., et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002, 35:20-29.
55. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
56. Falini B., Nicoletti I., Martelli M.F., Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109:874-885.
57. Verhaak R.G., Goudswaard C.S., van Putten W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005, 106:3747-3754.
58. Alcalay M., Tiacci E., Bergomas R., et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005, 106:899-902.
59. Mullighan C.G., Kennedy A., Zhou X., et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 2007, 21:2000-2009.
60. Wilson C.S., Davidson G.S., Martin S.B., et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006, 108:685-696.
61. Wouters B.J., Lowenberg B., Erpelinck-Verschueren C.A., et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113:3088-3091.
62. Kohlmann A., Bullinger L., Thiede C., et al. Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 2010, 10.1038/leu.2010.73.
63. Lacayo N.J., Meshinchi S., Kinnunen P., et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 2004, 104:2646-2654.
64. Bullinger L., Dohner K., Kranz R., et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008, 111:4490-4495.
65. Li Z., Lu J., Sun M., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008, 105:15535-15540.
66. Garzon R., Volinia S., Liu C.G., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
67. Jongen-Lavrencic M., Sun S.M., Dijkstra M.K., Valk P.J., Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111:5078-5085.
68. Haferlach T., Kohlmann A., Schnittger S., et al. AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer 2005, 43:113-127.
69. Silva F.P., Swagemakers S.M., Erpelinck-Verschueren C., et al. Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. Blood 2009, 114:3001-3007.
70. Rao A.V., Valk P.J., Metzeler K.H., et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009, 27:5580-5586.
71. Raponi M., Lancet J.E., Fan H., et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008, 111:2589-2596.
72. Gupta M., Raghavan M., Gale R.E., et al. Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 2008, 47:729-739.
73. Raghavan M., Smith L.L., Lillington D.M., et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 2008, 112:814-821.
74. Suela J., Alvarez S., Cifuentes F., et al. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 2007, 21:1224-1231.
75. Le Dieu R., Taussig D.C., Ramsay A.G., et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009, 114:3909-3916.
76. Galili N., Raza A. Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays. Best Pract Res Clin Haematol 2009, 22:223-237.
77. Pellagatti A., Marafioti T., Paterson J.C., et al. Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol 2009, 146:86-90.
78. Haferlach T., Kohlmann A., Wieczorek L., et al. The clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010, 28:2529-2537.
79. Mills K.I., Kohlmann A., Williams P.M., et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome (MDS). Blood 2009, 114:1063-1072.
80. Sridhar K., Ross D.T., Tibshirani R., Butte A.J., Greenberg P.L. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 2009, 114:4847-4854.
81. Prall W.C., Czibere A., Grall F., et al. Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome. Int J Hematol 2009, 89:173-187.
82. Miyazato A., Ueno S., Ohmine K., et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 2001, 98:422-427.
83. Raza A., Reeves J.A., Feldman E.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008, 111:86-93.
84. Armstrong S.A., Staunton J.E., Silverman L.B., et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002, 30:41-47.
85. Ross M.E., Zhou X., Song G., et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102:2951-2959.
86. Li Z., Zhang W., Wu M., et al. Gene expression-based classification and regulatory networks of pediatric acute lymphoblastic leukemia. Blood 2009, 114:4486-4493.
87. Fulci V., Colombo T., Chiaretti S., et al. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer 2009, 48:1069-1082.
88. Kern W., Kohlmann A., Wuchter C., et al. Correlation of protein expression and gene expression in acute leukemia. Cytom B Clin Cytom 2003, 55:29-36.
89. Chiaretti S., Li X., Gentleman R., et al. Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res 2005, 11:7209-7219.
90. Martinelli G., Iacobucci I., Storlazzi C.T., et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009, 27:5202-5207.
91. Iacobucci I., Storlazzi C.T., Cilloni D., et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009, 114:2159-2167.
92. Mullighan C.G., Su X., Zhang J., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360:470-480.
93. den Boer M.L., van Slegtenhorst M., De Menezes R.X., et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009, 10:125-134.
94. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009, 106:9414-9418.
95. Irving J.A., Bloodworth L., Bown N.P., et al. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Res 2005, 65:3053-3058.
96. Kawamata N., Ogawa S., Zimmermann M., et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2008, 111:776-784.
97. Mullighan C.G., Phillips L.A., Su X., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322:1377-1380.
98. Bardini M., Spinelli R., Bungaro S., et al. DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia 2009, 24:169-176.
99. Willenbrock H., Juncker A.S., Schmiegelow K., Knudsen S., Ryder L.P. Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays. Leukemia 2004, 18:1270-1277.
100. Bhojwani D., Kang H., Menezes R.X., et al. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study. J Clin Oncol 2008, 26:4376-4384.
101. Chiaretti S., Li X., Gentleman R., et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 2004, 103:2771-2778.
102. Hoffmann K., Firth M.J., Beesley A.H., et al. Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index. Br J Haematol 2008, 140:656-664.
103. Kang H., Chen I.M., Wilson C.S., et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2010, 115:1394-1405.
104. Hofmann W.K., de Vos S., Elashoff D., et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002, 359:481-486.
105. Zembutsu H., Yanada M., Hishida A., et al. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Int J Oncol 2007, 31:313-322.
106. Holleman A., Cheok M.H., den Boer M.L., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004, 351:533-542.
107. Coustan-Smith E., Mullighan C.G., Onciu M., et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009, 10:147-156.
108. Remke M., Pfister S., Kox C., et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood 2009, 114:1053-1062.
109. Lenz G., Wright G.W., Emre N.C., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008, 105:13520-13525.
110. Hummel M., Bentink S., Berger H., et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006, 354:2419-2430.
111. Hoelzer D., Gokbuget N. T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?. Clin Lymphoma Myeloma 2009, 9(Suppl. 3):S214-S221.
112. van Delft F.W., Bellotti T., Luo Z., et al. Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. Br J Haematol 2005, 130:26-35.
113. Haferlach T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2008, 1:400-411.
114. Stone R., Sekeres M., Garcia-Manero G. Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol 2009, 7:1-14.
115. Kenkre V.P., Stock W. Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma 2009, 9(Suppl. 3):S231-S238.
116. Kearney L., Horsley S.W. Molecular cytogenetics in haematological malignancy: current technology and future prospects. Chromosoma 2005, 114:286-294.
117. Chen J.S., Coustan-Smith E., Suzuki T., et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001, 97:2115-2120.
118. Steinbach D., Schramm A., Eggert A., et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 2006, 12:2434-2441.
119. Maher C.A., Kumar-Sinha C., Cao X., et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009, 458:97-101.
120. Gnirke A., Melnikov A., Maguire J., et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009, 27:182-189.
121. Ley T.J., Mardis E.R., Ding L., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456:66-72.
122. Walter M.J., Payton J.E., Ries R.E., et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA 2009, 106:12950-12955.